On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Walter Energy, (NYSE:WLT), Prana Biotechnology (NASDAQ:PRAN), Lion Biotechnologies (NASDAQ:LBIO),Organovo Holdings (NYSEMKT:ONVO), Teekay Tankers (NYSE:TNK)
Walter Energy, Inc.(NYSE:WLT)’s shares dwindled -6.98%, and closed at $.0570. The stock has price to sale ratio of 0.03, however, price to book ratio is 0.14. With recent decline, the year-to-date (YTD) performance reflected a -58.70% decline below last year. During the past month the stocks lose -41.24%, bringing three-month performance to -62.00% and six-month performance to -80.55%. The mean recommendation of analysts for this stock is 3.30. (where 1=Buy, 5=Sale).
Walter Energy, Inc. produces and exports metallurgical coal for the steel industry. It operates through two segments, U.S. Operations, and Canadian and U.K. Operations. The company also extracts, processes, markets, and/or possesses mineral reserves of thermal coal and anthracite coal, in addition to produces metallurgical coke and coal bed methane gas. As of December 31, 2014, it had about 392.7 million metric tons of recoverable reserves. Walter Energy, Inc. sells its metallurgical coal in Europe, Asia, and South America; and thermal coal primarily to large utilities and industrial customers located principally in Alabama, West Virginia, and the United Kingdom.
Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), declined -7.26%, and closed at $1.15. The company holds the market capitalization of $58.42M. For the last twelve months, the stock was able to keep return on equity at -104.80%, while return on assets at -88.20%, in response to its return on investment at -33.00%. Its 20-day moving average gained 0.37%, below 50-day moving average of -14.42%, below 200-day moving average of -37.56% from the latest market price of $1.15. The mean recommendation of analysts for this stock is 3.00.(where 1=Buy, 5=Sale).
Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs in Australia. The company offers PBT-2, a Phase IIa clinical trial product for the treatment of Alzheimer’s disease. Its product is designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company’s product is also applied for other therapies, counting age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinson’s disease, and other neurodegenerative diseases.
Lion Biotechnologies Inc (NASDAQ:LBIO), dipped -6.21%, and closed at $13.59, hitting new 52-week high of $15.03. The stock has the beta value of -104.25, and its volatility for the week is 10.11%, while for the month it is 10.12%. The company has the market capitalization of $599.05M. The company holds the book value per share of 1.62, whereas cash per share is 1.02. Price to book ratio remained 8.39, while price to cash ratio is 13.34. Analysts mean recommendation for the stock is said to be 1.80 (where 1=Buy, 5=sale).
Lion Biotechnologies, Inc., a development stage biotechnology company, develops T-cells and engineered T-cells for the treatment of various cancers. The company’s lead product candidate comprises a ready-to-infuse autologous T-cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with stage IV metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop and manufacture certain proprietary autologous TILs adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer; a cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes; and a process development and scale-up consulting agreement with Lonza Walkersville, Inc. to manufacture TILs.
Organovo Holdings Inc (NYSEMKT:ONVO), dropped -6.04%, and closed at $4.20.The company has the market capitalization of $337.93M. The beta value of the stock is -0.18. On the other hand the stock’s volatility for the week is 8.06%, and for the month is 6.94%. The stock’s price to book ratio is 844.72, however price to sale ratio is 7.00. Analyst’s mean recommendation regarding this stock is 3.00. (where 1=Buy, 5=Sale).
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, counting applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, in addition to functional tissue patches for the repair or replacement of damaged tissues and organs.
Teekay Tankers Ltd (NYSE:TNK), declined -5.71%, and closed at $5.45. The company holds the market capitalization of $604.28M. For the last twelve months, the stock was able to keep return on equity at 16.30%, while return on assets at 5.30%, in response to its return on investment at 5.20%. Its 20-day moving average declined -4.43%, below 50-day moving average of -4.64 %, above 200-day moving average of 20.33% from the latest market price of $5.45. The mean recommendation of analysts for this stock is 2.40.(where 1=Buy, 5=Sale).
Teekay Tankers Ltd., together with its subsidiaries, is engaged in the marine transportation of crude oil and refined petroleum products worldwide. It owns and operates crude oil and product tankers. As of April 30, 2014, it owned a fleet of 29 double-hull vessels, counting 11 Aframax tankers, 10 Suezmax tankers, 2 very large crude carrier tankers, 3 long range 2 product tankers, 3 medium-range product tankers, and 1 time-chartered in Aframax tanker, in addition to a 50%-owned very large crude carrier tanker. Teekay Tankers Ltd. is headquartered in Hamilton, Bermuda.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
